Identification

Name
Folic Acid
Accession Number
DB00158  (NUTR00025)
Type
Small Molecule
Groups
Approved, Nutraceutical, Vet Approved
Description

A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (poaceae). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia. [PubChem]

Structure
Thumb
Synonyms
  • Folacin
  • Folate
  • Folic acid
  • Folsaeure
  • N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
  • N-Pteroyl-L-glutamic acid
  • PGA
  • PteGlu
  • Pteroyl-L-glutamate
  • Pteroyl-L-glutamic acid
  • Pteroyl-L-monoglutamic acid
  • Pteroylglutamic acid
  • Vitamin B9
  • Vitamin Bc
  • Vitamin M
External IDs
B03BB01 / NSC-3073
Product Ingredients
IngredientUNIICASInChI Key
Folate sodium9P9W8GGU786484-89-5SWIRFWUEJODNRG-CURYUGHLSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acide Folique 5 TabTablet5 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Euro-folic 5mgTablet5 mgOralSandoz Canada Incorporated2006-11-27Not applicableCanada
Folic AcidTablet1 mg/1OralApace Packaging2009-12-23Not applicableUs
Folic Acid 0.4mgTablet0.4 mgOralLeiner Health ProductsNot applicableNot applicableCanada
Folic Acid Inj 5mg/ml USPLiquid5 mgIntramuscular; Intravenous; SubcutaneousLyphomed, Division Of Fujisawa Canada Inc.1993-12-311996-09-10Canada
Folic Acid InjectionSolution5 mgIntramuscular; Intravenous; SubcutaneousFresenius Kabi1996-08-14Not applicableCanada
Folic Acid Injection USPLiquid5 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1990-12-31Not applicableCanada
Folic Acid Tab 25mgTablet25 mgOralKripps Pharmacy Ltd.1975-12-31Not applicableCanada
Folic Acid Tab 5mgTablet5 mgOralPendopharm Division Of De Pharmascience Inc1980-12-31Not applicableCanada
Folic Acid Tab 5mgTablet5 mgOralKripps Pharmacy Ltd.1975-12-311997-08-01Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Folic Acid Tab 5mgTablet5 mgOralApotex Corporation1978-12-31Not applicableCanada
Folic AcidTablet1 mg/1OralCardinal Health2011-05-20Not applicableUs
Folic AcidTablet1 mg/1OralA S Medication Solutions2009-06-092017-06-20Us
Folic AcidTablet1 mg/1OralRemedy Repack2017-07-06Not applicableUs
Folic AcidTablet1 mg/1OralBlu Pharmceuticals Llc2010-11-012017-05-11Us
Folic AcidTablet1 mg/1OralSunrise Pharmaceutical, Inc.2015-08-04Not applicableUs
Folic AcidTablet1 mg/1OralTYA Pharmaceuticals2009-12-02Not applicableUs
Folic AcidTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.2015-08-04Not applicableUs
Folic AcidTablet1 mg/1OralMylan Institutional2011-04-21Not applicableUs
Folic AcidTablet1 mg/1OralMc Kesson Contract Packaging2012-03-05Not applicableUs00143 9717 10 nlmimage10 9807cc5e
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Folic AcidCapsule1 mgOralSisu Inc.1999-08-032006-07-31Canada
Folic Acid (1mg Tablet)Tablet1 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1997-10-102002-07-31Canada
Folic Acid 0.4 Mg TabletTablet0.4 mgOralSwiss Herbal Remedies Ltd.1999-12-062007-07-31Canada
Folic Acid 0.4mgTablet0.4 mgOralGreat Earth Companies, Inc.1998-08-252002-10-02Canada
Folic Acid 0.4mg Dietary SupplementTablet0.4 mgOralGarden State Nutritionals1998-08-312000-06-07Canada
Folic Acid 0.8mgTablet0.8 mgOralGreat Earth Companies, Inc.1998-08-252002-10-02Canada
Folic Acid 1 mgTablet1 mgOralPreferred Nutrition Inc.2004-04-282005-08-04Canada
Folic Acid 1 Mg - TabletTablet1 mgOralHealth Wise Nutrition Inc.1996-10-222002-07-18Canada
Folic Acid 1mgTablet1.0 mgOralWn Pharmaceuticals Ltd.2002-04-152006-08-08Canada
Folic Acid 1mgTablet1 mgOralJamieson Laboratories Ltd1994-12-311997-08-13Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Folic AcidTablet1 mg/1OralMajor2010-06-04Not applicableUs
Folic AcidTablet1 mg/1OralRemedy Repack2017-11-24Not applicableUs
Folic AcidTablet1 mg/1OralPreferreed Pharmaceuticals Inc.2017-11-06Not applicableUs
Folic AcidTablet1 mg/1OralAphena Pharma Solutions Tennessee, Inc.2016-02-01Not applicableUs
International/Other Brands
Acfol (Cazi) / Fefol (GlaxoSmithKline)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
A.R.T.H. Away FormulaFolic Acid (0.025 mg) + Calcium (24 mg) + Cholecalciferol (45 unit) + Copper (0.232 mg) + Manganese (0.58 mg) + Pyridoxine hydrochloride (0.5 mg) + Selenium (1.54 mcg) + Zinc (0.63 mg)CapsuleOralAbundance Marketing Ltd.1999-02-012006-06-16Canada
Acti-folic + Dibencozide CapletsFolic Acid (1 mg) + Cobamamide (40 mcg)TabletOralActi Form Ltd.1991-12-312005-03-21Canada
Active FEFolic Acid (1250 ug/1) + Beta carotene (2100 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (30 ug/1) + Iron (75 mg/1) + Magnesium oxide (30 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (4 mg/1) + Thiamine Hydrochloride (4 mg/1) + Vitamin C (160 mg/1) + Vitamin E (40 [iU]/1) + Zinc oxide (20 mg/1)TabletOralGm Pharmaceuticals2013-11-11Not applicableUs
Adult Infuvite Multiple VitaminsFolic Acid (600 ug/10mL) + Biotin (60 ug/10mL) + Cholecalciferol (200 [iU]/10mL) + Cyanocobalamin (5 ug/10mL) + Dexpanthenol (15 mg/10mL) + Nicotinamide (40 mg/10mL) + Phylloquinone (150 ug/10mL) + Pyridoxine hydrochloride (6 mg/10mL) + Riboflavin 5'-phosphate sodium (3.6 mg/10mL) + Thiamine Hydrochloride (6 mg/10mL) + Vitamin A palmitate (3300 [iU]/10mL) + Vitamin C (200 mg/10mL) + Vitamin E acetate (10 [iU]/10mL)Injection, solutionIntravenousSandoz2003-06-16Not applicableUs
Adult Infuvite Multiple VitaminsFolic Acid (600 ug/10mL) + Biotin (60 ug/10mL) + Cholecalciferol (200 [iU]/10mL) + Cyanocobalamin (5 ug/10mL) + Dexpanthenol (15 mg/10mL) + Nicotinamide (40 mg/10mL) + Phylloquinone (150 ug/10mL) + Pyridoxine hydrochloride (6 mg/10mL) + Riboflavin 5'-phosphate sodium (3.6 mg/10mL) + Thiamine Hydrochloride (6 mg/10mL) + Vitamin A palmitate (3300 [iU]/10mL) + Vitamin C (200 mg/10mL) + Vitamin E acetate (10 [iU]/10mL)Injection, solutionIntravenousSandoz2005-05-18Not applicableUs
Adult Infuvite Multiple VitaminsFolic Acid (600 ug/10mL) + Biotin (60 ug/10mL) + Cholecalciferol (200 [iU]/10mL) + Cyanocobalamin (5 ug/10mL) + Dexpanthenol (15 mg/10mL) + Nicotinamide (40 mg/10mL) + Phylloquinone (150 ug/10mL) + Pyridoxine hydrochloride (6 mg/10mL) + Riboflavin 5'-phosphate sodium (3.6 mg/10mL) + Thiamine Hydrochloride (6 mg/10mL) + Vitamin A palmitate (3300 [iU]/10mL) + Vitamin C (200 mg/10mL) + Vitamin E acetate (10 [iU]/10mL)Injection, solutionIntravenousSandoz2005-05-18Not applicableUs
Adult Infuvite Multiple VitaminsFolic Acid (600 ug/10mL) + Biotin (60 ug/10mL) + Cholecalciferol (200 [iU]/10mL) + Cyanocobalamin (5 ug/10mL) + Dexpanthenol (15 mg/10mL) + Nicotinamide (40 mg/10mL) + Phylloquinone (150 ug/10mL) + Pyridoxine hydrochloride (6 mg/10mL) + Riboflavin 5'-phosphate sodium (3.6 mg/10mL) + Thiamine Hydrochloride (6 mg/10mL) + Vitamin A palmitate (3300 [iU]/10mL) + Vitamin C (200 mg/10mL) + Vitamin E acetate (10 [iU]/10mL)Injection, solutionIntravenousSandoz2003-06-16Not applicableUs
Am CapsFolic Acid (0.20 mg) + Beta carotene (2500 unit) + Biotin (150 mcg) + Cholecalciferol (200 unit) + Cyanocobalamin (5 mcg) + Nicotinamide (10 mg) + Pyridoxine hydrochloride (1 mg) + Riboflavin (0.85 mg) + Selenium (50 mcg) + Thiamine (0.75 mg) + Calcium ascorbate (30 mg) + Vitamin E (15 unit)CapsuleOralNew Vision Nutritionals CompanyNot applicableNot applicableCanada
Am CapsFolic Acid (0.2 mg) + Biotin (150 mcg) + Cyanocobalamin (3 mcg) + Nicotinamide (10 mg) + Pyridoxine hydrochloride (1 mg) + Riboflavin (0.90 mg) + Thiamine (0.75 mg) + Vitamin A (1250 unit) + Vitamin C (30 mg) + Vitamin D (100 unit)CapsuleOralNew Vision Nutritionals Company1998-10-012002-11-20Canada
Animi-3Folic Acid (1 mg/1) + Cholecalciferol (1000 [iU]/1) + Cyanocobalamin (500 ug/1) + Doconexent (250 mg/1) + Icosapent (35 mg/1) + Omega-3 fatty acids (500 mg/1) + Pyridoxine hydrochloride (12.5 mg/1) + Soy sterol (200 mg/1)CapsuleOralPbm Pharmaceuticals Inc.2011-06-01Not applicableUs
Categories
UNII
935E97BOY8
CAS number
59-30-3
Weight
Average: 441.3975
Monoisotopic: 441.139681375
Chemical Formula
C19H19N7O6
InChI Key
OVBPIULPVIDEAO-LBPRGKRZSA-N
InChI
InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
IUPAC Name
(2S)-2-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid
SMILES
NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[[email protected]@H](CCC(O)=O)C(O)=O)=CN=C2N1

Pharmacology

Indication

For treatment of folic acid deficiency, megaloblastic anemia and in anemias of nutritional supplements, pregnancy, infancy, or childhood.

Structured Indications
Not Available
Pharmacodynamics

Folic acid, a water-soluble B-complex vitamin, is found in foods such as liver, kidneys, yeast, and leafy, green vegetables. Folic acid is used to diagnose folate deficiency and to treat topical sprue and megaloblastic and macrocytic anemias, hematologic complications resulting from a deficiency in folic acid.

Mechanism of action

Folic acid, as it is biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase. These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylate tRNA, and generate and use formate. Using vitamin B12 as a cofactor, folic acid can normalize high homocysteine levels by remethylation of homocysteine to methionine via methionine synthetase.

TargetActionsOrganism
UFolate receptor beta
binder
Human
UFolate receptor gamma
binder
Human
UFolate receptor alphaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

Very high to plasma protein

Metabolism

Hepatic

Route of elimination

Folic Acid is metabolized in the liver to 7, 8-dihydrofolic acid and eventually to 5,6,7,8-tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide (DPNH) and folate reductases. A majority of the metabolic products appeared in the urine after 6 hours; excretion was generally complete within 24 hours. Folic Acid is also excreted in the milk of lactating mothers.

Half life
Not Available
Clearance
Not Available
Toxicity

IPR-MUS LD50 85 mg/kg,IVN-GPG LD50 120 mg/kg, IVN-MUS LD50 239 mg/kg, IVN-RAT LD50 500 mg/kg, IVN-RBT LD50 410 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)Disease
Methotrexate Action PathwayDrug action
Folate MetabolismMetabolic
Folate malabsorption, hereditaryDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlminoprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Alminoprofen.Experimental
AndrographolideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Andrographolide.Investigational
AnisodamineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Apremilast.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Balsalazide.Approved, Investigational
BendazacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Benzydamine.Approved
BevoniumThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bevonium.Experimental
BromfenacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bucillamine.Investigational
BufexamacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bufexamac.Experimental
BumadizoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bumadizone.Experimental
CarprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Celecoxib.Approved, Investigational
ChloroquineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Chloroquine.Approved, Vet Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Choline magnesium trisalicylate.Approved
ClonixinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Clonixin.Approved
ClotrimazoleThe metabolism of Folic Acid can be decreased when combined with Clotrimazole.Approved, Vet Approved
CurcuminThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Curcumin.Investigational
Cyproterone acetateThe serum concentration of Folic Acid can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with D-Limonene.Investigational
DiclofenacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DifenpiramideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Diflunisal.Approved
DroxicamThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Folic Acid can be decreased when used in combination with E-6201.Investigational
EltrombopagThe serum concentration of Folic Acid can be increased when it is combined with Eltrombopag.Approved
EpirizoleThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Epirizole.Approved
EtanerceptThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ethenzamide.Experimental
EtodolacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Evening primrose oil.Approved, Investigational
exisulindThe therapeutic efficacy of Folic Acid can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ferulic acid.Experimental
FloctafenineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Flunoxaprofen.Experimental
FlurbiprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Folic Acid.Approved
GuacetisalThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Guacetisal.Experimental
HigenamineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Higenamine.Investigational
IbuprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Icatibant.Approved
Imidazole salicylateThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Imidazole salicylate.Experimental
IndobufenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Indoprofen.Withdrawn
IsoniazidThe metabolism of Folic Acid can be decreased when combined with Isoniazid.Approved
IsoxicamThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Isoxicam.Withdrawn
KebuzoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Kebuzone.Experimental
KetoprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketorolac.Approved
LeflunomideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Leflunomide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lisofylline.Investigational
LonazolacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lornoxicam.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Masoprocol.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Metamizole.Investigational, Withdrawn
MizoribineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mizoribine.Investigational
MofebutazoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mofebutazone.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Naftifine.Approved
NaproxenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Naproxen.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nepafenac.Approved
NicotineThe metabolism of Folic Acid can be decreased when combined with Nicotine.Approved
NifenazoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nitroaspirin.Investigational
OlopatadineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olsalazine.Approved
OrgoteinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxaprozin.Approved
OxyphenbutazoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Parecoxib.Approved
ParthenolideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Parthenolide.Investigational
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Folic Acid.Approved
PhenylbutazoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Folic Acid.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirfenidoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiroxicamThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pirprofen.Experimental
PranoprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrimidoneThe serum concentration of Primidone can be decreased when it is combined with Folic Acid.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Propacetamol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Proquazone.Experimental
PTC299The therapeutic efficacy of Folic Acid can be decreased when used in combination with PTC299.Investigational
RaltitrexedThe therapeutic efficacy of Raltitrexed can be decreased when used in combination with Folic Acid.Approved, Investigational
ResveratrolThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RofecoxibThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RolapitantThe serum concentration of Folic Acid can be increased when it is combined with Rolapitant.Approved
SalicylamideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salsalate.Approved
SemapimodThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Serrapeptase.Investigational
SRT501The therapeutic efficacy of Folic Acid can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe serum concentration of Folic Acid can be decreased when it is combined with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Sulindac.Approved
SuprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Suxibuzone.Experimental
TarenflurbilThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tarenflurbil.Investigational
TenidapThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe serum concentration of Folic Acid can be increased when it is combined with Teriflunomide.Approved
Tiaprofenic acidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tiaprofenic acid.Approved
TiclopidineThe metabolism of Folic Acid can be decreased when combined with Ticlopidine.Approved
TinoridineThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tinoridine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tolmetin.Approved
TranilastThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tranilast.Approved, Investigational
TribenosideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tribenoside.Experimental
TriptolideThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Triptolide.Investigational
ValdecoxibThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ZaltoprofenThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Carroll G. Temple, Jr., Robert D. Elliott, Jerry D. Rose, John A. Montgomery, "Preparation of tetrahydrofolic acid from folic acid." U.S. Patent US4206307, issued April, 1956.

US4206307
General References
  1. Kamen B: Folate and antifolate pharmacology. Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-30-S18-39. [PubMed:9420019]
  2. Fenech M, Aitken C, Rinaldi J: Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults. Carcinogenesis. 1998 Jul;19(7):1163-71. [PubMed:9683174]
  3. Zittoun J: [Anemias due to disorder of folate, vitamin B12 and transcobalamin metabolism]. Rev Prat. 1993 Jun 1;43(11):1358-63. [PubMed:8235383]
  4. Alaimo K, McDowell MA, Briefel RR, Bischof AM, Caughman CR, Loria CM, Johnson CL: Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. Adv Data. 1994 Nov 14;(258):1-28. [PubMed:10138938]
  5. Raiten DJ, Fisher KD: Assessment of folate methodology used in the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). J Nutr. 1995 May;125(5):1371S-1398S. [PubMed:7738698]
External Links
Human Metabolome Database
HMDB00121
KEGG Drug
D00070
KEGG Compound
C00504
PubChem Compound
6037
PubChem Substance
46508092
ChemSpider
5815
BindingDB
50367343
ChEBI
27470
ChEMBL
CHEMBL1622
Therapeutic Targets Database
DAP001309
PharmGKB
PA449692
HET
FOL
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Folic_Acid
ATC Codes
B03AE01 — Iron, vitamin b12 and folic acidB03AE02 — Iron, multivitamins and folic acidB03BB51 — Folic acid, combinationsB03BB01 — Folic acid
AHFS Codes
  • 88:08.00 — Vitamin B Complex
PDB Entries
1cd2 / 1dhf / 1drf / 1dyi / 1pj6 / 1qzf / 1ra2 / 1ra8 / 1rb2 / 1rd7
show 56 more
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer (NSCLC) / Cancer, Ovarian / Non Small Cell Lung Carcinoma (NSCLC) / Triple-Negative Breast Cancer (TNBC) / Tumors, Solid1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I / Mycobacterium avium complex infection1
1CompletedDiagnosticHealthy Volunteers1
1CompletedOtherHeart Rate / Heart Rate Variability / Inflammatory Reaction1
1CompletedPreventionHIV-infection/Aids1
1CompletedPreventionHealthy Volunteers / Pharmacokinetics1
1CompletedPreventionRecurrent Neural Tube Defects1
1CompletedTreatmentCancers / Metastases1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentRheumatoid Arthritis2
1Not Yet RecruitingBasic ScienceAging / Mineral deficiency / Vitamin Deficiency1
1RecruitingBasic ScienceOvary Cancer1
1RecruitingDiagnosticMetastatic Cancer Lung / Ovarian Cancer Metastatic1
1RecruitingTreatmentLeptomeningeal Metastases1
1, 2Not Yet RecruitingTreatmentCecal Neoplasms / Metastases to peritoneum / Neoplasms, Colorectal / Peritoneal Carcinomatosis1
1, 2RecruitingTreatmentPolycystic Ovaries Syndrome1
1, 2RecruitingTreatmentPostpartum Anemia1
1, 2SuspendedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1, 2TerminatedTreatmentPsoriasis1
2Active Not RecruitingTreatmentLung Cancers / Neoplasms Metastasis1
2Active Not RecruitingTreatmentRheumatoid Arthritis2
2CompletedPreventionAdenoma benign / Colorectal Polyps / Malignant Neoplasm of Colon1
2CompletedPreventionDepression / Depressive Disorders1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentChronic Arsenic Poisoning1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLupus / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentRheumatoid Arthritis4
2Not Yet RecruitingTreatmentRheumatoid Arthritis1
2RecruitingPreventionPeripheral T-cell lymphoma unspecified refractory / Relapsed Peripheral T-Cell Lymphoma1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kidney Diseases1
2RecruitingTreatmentMetastatic Colorectal Cancers1
2RecruitingTreatmentRheumatoid Arthritis2
2TerminatedTreatmentInfertilities1
2Unknown StatusPreventionArsenic Poisoning / Toxic Effect of Arsenic and Its Compounds1
2Unknown StatusPreventionCoronary Artery Disease1
2Unknown StatusTreatmentAfter Resection of Liver Metastases / Colorectal Cancers / KRAS Wildtype1
2Unknown StatusTreatmentAnemias1
2WithdrawnTreatmentNeoplasms, Breast1
2, 3CompletedPreventionAdenoma benign / Colorectal Cancers / Polyps1
2, 3CompletedTreatmentAtherosclerosis1
2, 3CompletedTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Mortality1
2, 3CompletedTreatmentDiabetic Nephropathies1
2, 3CompletedTreatmentRheumatoid Arthritis1
2, 3RecruitingPreventionGestational Diabetes Mellitus (GDM) / Polycystic Ovaries Syndrome1
2, 3RecruitingPreventionNeoplasms, Colorectal1
3CompletedPreventionCleft Lip / Cleft Palates1
3CompletedPreventionComplications, Pregnancy / Preeclampsia1
3CompletedPreventionGingival Overgrowth1
3CompletedPreventionPlasmodium Infections1
3CompletedTreatmentActive Rheumatoid Arthritis1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAnemias1
3CompletedTreatmentContraception1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis, Pulmonary1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentMale Infertility1
3CompletedTreatmentMycobacterium Tuberculosis1
3CompletedTreatmentRheumatoid Arthritis5
3CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
3RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma / Ureteral Cancer1
3RecruitingTreatmentRheumatoid Arthritis1
3TerminatedPreventionBlood Loss / Pregnancy termination therapy1
3Unknown StatusNot AvailableAnemias / Low Birth Weight / Neonatal Mortality1
3Unknown StatusPreventionCongenital Malformations1
3Unknown StatusPreventionEpilepsies1
3Unknown StatusTreatmentAlzheimer's Disease (AD) / Down Syndrome (DS)1
4Active Not RecruitingBasic SciencePsoriasis1
4CompletedNot AvailableMetabolic Syndromes1
4CompletedPreventionAnovulatory cycle / Polycystic Ovaries Syndrome1
4CompletedPreventionCardiovascular Disease (CVD) / Chronic Renal Failure (CRF) / Hemodialysis-dependent patients / Hyperhomocysteinaemia / Uremia1
4CompletedPreventionPostpartum Hemorrhage1
4CompletedTreatmentBMI >30 kg/m2 / Hyperhomocysteinaemia1
4CompletedTreatmentDepression1
4CompletedTreatmentDiabetic Peripheral Neuropathic Pain1
4CompletedTreatmentHyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting1
4CompletedTreatmentHyperpigmentation1
4CompletedTreatmentNegative Symptoms / Schizophrenic Disorders1
4CompletedTreatmentPregnancy1
4CompletedTreatmentRecurrent Miscarriages1
4CompletedTreatmentRheumatoid Arthritis2
4CompletedTreatmentSchizophrenic Disorders1
4CompletedTreatmentUnipolar Depression1
4Not Yet RecruitingTreatmentFaltering Growth / Primary Malnurtrition1
4RecruitingPreventionKidney Diseases / Urologic Diseases1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingTreatmentRheumatoid Arthritis1
4TerminatedDiagnosticTransplantation, Kidney1
4TerminatedTreatmentAnemias1
4TerminatedTreatmentHeart Failure, Unspecified1
4TerminatedTreatmentRheumatoid Arthritis1
4Unknown StatusNot AvailableGestational Diabetes Mellitus (GDM)1
4Unknown StatusTreatmentNonulcer Dyspepsia1
4WithdrawnTreatmentNephritis / Proteinuria / Systemic Lupus Erythematosus (SLE)1
Not AvailableActive Not RecruitingNot AvailableAtherosclerosis / Human Immunodeficiency Virus (HIV) / Inflammatory Reaction1
Not AvailableCompletedNot AvailableAnemias1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedDiagnosticCoronary Artery Disease / Major Surgery1
Not AvailableCompletedPreventionBipolar Disorder (BD) / Depression1
Not AvailableCompletedPreventionNeural Tube Defects (NTDs)1
Not AvailableCompletedPreventionNeural Tube Defects - Spina Bifida and Anencephaly1
Not AvailableCompletedPreventionSpina Bifida and Anencephaly1
Not AvailableCompletedTreatmentAcute Myocardial Infarction (AMI)1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Hyperhomocysteinaemia1
Not AvailableCompletedTreatmentEnd Stage Renal Disease (ESRD) / Hyperhomocysteinaemia1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHyperandrogenism / Menstrual Pattern / Metabolic Features / Polycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentHyperhomocysteinaemia / Inflammatory Reaction / Mortality1
Not AvailableTerminatedTreatmentAbortion, Therapeutic / Pregnancy Trimester, Second1
Not AvailableUnknown StatusTreatmentAbnormal Uterine Bleeding Unrelated to Menstrual Cycle1
Not AvailableUnknown StatusTreatmentFolic acid antagonist overdose1
Not AvailableWithdrawnPreventionStrokes / Transient Ischaemic Attack (TIA)1

Pharmacoeconomics

Manufacturers
  • App pharmaceuticals llc
  • Ben venue laboratories inc
  • Wyeth pharmaceuticals inc
  • Barr laboratories inc
  • Cadista pharmaceuticals inc
  • Contract pharmacal corp
  • Everylife
  • Excellium pharmaceutical inc
  • Halsey drug co inc
  • Impax laboratories inc
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lannett co inc
  • Eli lilly and co
  • Mk laboratories inc
  • Mutual pharmaceutical co inc
  • Nexgen pharma inc
  • Pharmax group inc
  • Pharmeral inc
  • Pioneer pharmaceuticals inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Tablicaps inc
  • Udl laboratories inc
  • Usl pharma inc
  • Valeant pharmaceuticals international
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals llc
  • Vintage pharmaceuticals inc
  • Watson laboratories
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Mission pharmacal co
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
Tablet, extended releaseOral
TabletOral
SolutionOral
Granule, effervescentOral
WaferOral
Capsule, liquid filledOral
Tablet, effervescentOral
Capsule, delayed release pelletsOral
LiquidOral
Injection, solutionIntramuscular; Intravenous; Subcutaneous5 mg/mL
TabletOral1 mg/1
TabletOral0.4 mg
TabletOral1 mg
TabletOral1.0 mg
TabletOral.4 mg
TabletOral.8 mg
CapsuleOral1 mg
Tablet, extended releaseOral800 mcg
SolutionIntramuscular; Intravenous; Subcutaneous5 mg
LiquidIntramuscular; Intravenous; Subcutaneous5 mg
TabletOral25 mg
TabletOral0.8 mg
Tablet, film coatedOral
PowderOral
Tablet, chewableOral
Solution / dropsOral
LiquidIntravenous
Injection, powder, lyophilized, for solutionIntravenous
Injection, solution, concentrateIntravenous
SolutionIntravenous
Injection, solutionIntravenous
Kit
Tablet, coatedOral
Powder, for solutionOral
Capsule, gelatin coatedOral
KitOral
LozengeOral
Capsule, extended releaseOral
CapsuleOral
Prices
Unit descriptionCostUnit
Folic acid 5 mg/ml vial2.14USD ml
Folic Acid 5 mg/ml2.04USD ml
Folic acid powder1.68USD g
Folvite 5 mg/ml vial1.38USD ml
Folic Acid 1 mg tablet0.15USD tablet
Folic acid 400 mcg tablet0.07USD tablet
Apo-Folic 5 mg Tablet0.04USD tablet
CVS Pharmacy folic acid 800 mcg tablet0.02USD tablet
Folic acid 0.4 mg tablet0.02USD tablet
Folic acid 0.8 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)250 dec °CPhysProp
water solubility1.6 mg/L (at 25 °C)MERCK INDEX (1983)
logP-2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0761 mg/mLALOGPS
logP-0.04ALOGPS
logP-0.68ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.37ChemAxon
pKa (Strongest Basic)2.09ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area208.99 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity111.01 m3·mol-1ChemAxon
Polarizability42.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7956
Blood Brain Barrier+0.7609
Caco-2 permeable-0.844
P-glycoprotein substrateSubstrate0.687
P-glycoprotein inhibitor INon-inhibitor0.9795
P-glycoprotein inhibitor IINon-inhibitor0.9969
Renal organic cation transporterNon-inhibitor0.876
CYP450 2C9 substrateNon-substrate0.8276
CYP450 2D6 substrateNon-substrate0.7947
CYP450 3A4 substrateNon-substrate0.6212
CYP450 1A2 substrateNon-inhibitor0.9281
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9435
CYP450 2C19 inhibitorNon-inhibitor0.916
CYP450 3A4 inhibitorNon-inhibitor0.9075
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.974
Ames testNon AMES toxic0.8724
CarcinogenicityNon-carcinogens0.9521
BiodegradationNot ready biodegradable0.9191
Rat acute toxicity2.4490 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9529
hERG inhibition (predictor II)Non-inhibitor0.8444
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0006-9410000000-7cba521e870757539424
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-0006-0000900000-4208ea3c2f5d9026c19f
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-0006-0050900000-2c8ad037dc3b270765c4
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0007-0090300000-ebdec84cbb7fe5afbc0b
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-0007-0903600000-e5d91e4f2ab79d130b76
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0007-0903600000-e5d91e4f2ab79d130b76
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002b-0960000000-108d96993dc78f1e4b61
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Glutamic acid and derivatives
Alternative Parents
N-acyl-alpha amino acids / Hippuric acids / Pterins and derivatives / Aminobenzamides / Phenylalkylamines / Aniline and substituted anilines / Benzoyl derivatives / Secondary alkylarylamines / Hydroxypyrimidines / Pyrazines
show 10 more
Substituents
Glutamic acid or derivatives / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / Hippuric acid / Hippuric acid or derivatives / Pterin / Aminobenzamide / Aminobenzoic acid or derivatives / Pteridine / Benzamide
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-acyl-amino acid, folic acids (CHEBI:27470) / Water-soluble vitamins (C00504)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Methotrexate binding
Specific Function
Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analo...
Gene Name
FOLR2
Uniprot ID
P14207
Uniprot Name
Folate receptor beta
Molecular Weight
29279.31 Da
References
  1. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP: Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem. 2006 May-Jun;17(3):603-9. [PubMed:16704197]
  2. Wlodarczyk BJ, Cabrera RM, Hill DS, Bozinov D, Zhu H, Finnell RH: Arsenic-induced gene expression changes in the neural tube of folate transport defective mouse embryos. Neurotoxicology. 2006 Jul;27(4):547-57. Epub 2006 Apr 18. [PubMed:16620997]
  3. Boyles AL, Billups AV, Deak KL, Siegel DG, Mehltretter L, Slifer SH, Bassuk AG, Kessler JA, Reed MC, Nijhout HF, George TM, Enterline DS, Gilbert JR, Speer MC: Neural tube defects and folate pathway genes: family-based association tests of gene-gene and gene-environment interactions. Environ Health Perspect. 2006 Oct;114(10):1547-52. [PubMed:17035141]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Folic acid binding
Specific Function
Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. Isoform Short does not bind folate.
Gene Name
FOLR3
Uniprot ID
P41439
Uniprot Name
Folate receptor gamma
Molecular Weight
27638.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Shen F, Ross JF, Wang X, Ratnam M: Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994 Feb 8;33(5):1209-15. [PubMed:8110752]
  4. Shen F, Wu M, Ross JF, Miller D, Ratnam M: Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 1995 Apr 25;34(16):5660-5. [PubMed:7727426]
  5. Prasad PD, Ramamoorthy S, Moe AJ, Smith CH, Leibach FH, Ganapathy V: Selective expression of the high-affinity isoform of the folate receptor (FR-alpha) in the human placental syncytiotrophoblast and choriocarcinoma cells. Biochim Biophys Acta. 1994 Aug 11;1223(1):71-5. [PubMed:8061055]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analo...
Gene Name
FOLR1
Uniprot ID
P15328
Uniprot Name
Folate receptor alpha
Molecular Weight
29818.94 Da
References
  1. Wang L, Desmoulin SK, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang MH, Mitchell-Ryan S, Stout M, Romero MF, Hou Z, Matherly LH, Gangjee A: Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits beta-glycinamide ribonucleotide formyltransferase. J Med Chem. 2011 Oct 27;54(20):7150-64. doi: 10.1021/jm200739e. Epub 2011 Sep 22. [PubMed:21879757]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Omega peptidase activity
Specific Function
Hydrolyzes the polyglutamate sidechains of pteroylpolyglutamates. Progressively removes gamma-glutamyl residues from pteroylpoly-gamma-glutamate to yield pteroyl-alpha-glutamate (folic acid) and fr...
Gene Name
GGH
Uniprot ID
Q92820
Uniprot Name
Gamma-glutamyl hydrolase
Molecular Weight
35964.045 Da
References
  1. Schneider E, Ryan TJ: Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta. 2006 Dec;374(1-2):25-32. Epub 2006 Jun 10. [PubMed:16859665]
  2. Eisele LE, Chave KJ, Lehning AC, Ryan TJ: Characterization of Human gamma-glutamyl hydrolase in solution demonstrates that the enzyme is a non-dissociating homodimer. Biochim Biophys Acta. 2006 Sep;1764(9):1479-86. Epub 2006 Jul 12. [PubMed:16945597]
  3. Chen L, Eitenmiller RR: Optimization of the trienzyme extraction for the microbiological assay of folate in vegetables. J Agric Food Chem. 2007 May 16;55(10):3884-8. Epub 2007 Apr 17. [PubMed:17439143]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein complex binding
Specific Function
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Gene Name
MTHFR
Uniprot ID
P42898
Uniprot Name
Methylenetetrahydrofolate reductase
Molecular Weight
74595.895 Da
References
  1. West AA, Caudill MA: Genetic variation: impact on folate (and choline) bioefficacy. Int J Vitam Nutr Res. 2010 Oct;80(4-5):319-29. doi: 10.1024/0300-9831/a000040. [PubMed:21462116]
  2. Kim YI: Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol. 2009 May;5(4):523-42. doi: 10.2217/fon.09.26. [PubMed:19450180]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Christensen U, Holm J, Hansen SI: Stopped-flow kinetic studies of the interaction of bovine folate binding protein (FBP) and folate. Biosci Rep. 2006 Aug;26(4):291-9. [PubMed:17029005]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Purine nucleotide transmembrane transporter activity
Specific Function
Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a ...
Gene Name
ABCC11
Uniprot ID
Q96J66
Uniprot Name
ATP-binding cassette sub-family C member 11
Molecular Weight
154299.625 Da
References
  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927]
  2. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. [PubMed:12883481]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]
  2. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. [PubMed:9827570]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54. [PubMed:12874005]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Methotrexate transporter activity
Specific Function
Has been shown to act both as an intestinal proton-coupled high-affinity folate transporter and as an intestinal heme transporter which mediates heme uptake from the gut lumen into duodenal epithel...
Gene Name
SLC46A1
Uniprot ID
Q96NT5
Uniprot Name
Proton-coupled folate transporter
Molecular Weight
49770.04 Da
References
  1. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, Yuasa H: Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007 Aug;322(2):469-76. Epub 2007 May 2. [PubMed:17475902]
  2. Ashokkumar B, Mohammed ZM, Vaziri ND, Said HM: Effect of folate oversupplementation on folate uptake by human intestinal and renal epithelial cells. Am J Clin Nutr. 2007 Jul;86(1):159-66. [PubMed:17616776]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Folic acid transporter activity
Specific Function
Transports folate across the inner membranes of mitochondria.
Gene Name
SLC25A32
Uniprot ID
Q9H2D1
Uniprot Name
Mitochondrial folate transporter/carrier
Molecular Weight
35406.83 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18